Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion (NYSE: AORT) has closed its acquisition of Endospan, a pioneer in endovascular solutions for complex aortic pathologies. The deal follows the April 2026 FDA PMA approval of Endospan’s NEXUS Aortic Arch System, the first off-the-shelf endovascular solution for aortic arch disease. The base purchase price is $175 million (less loan offsets), with up to $200 million in additional earn-out consideration tied to U.S. commercial performance over two years.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.